找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Clinician’s Manual: Treatment of Hypertension; Third Edition Franz H Messerli Book 2011Latest edition Springer Healthcare Ltd. 2011 Clinica

[复制链接]
楼主: intern
发表于 2025-3-25 05:19:01 | 显示全部楼层
发表于 2025-3-25 11:00:06 | 显示全部楼层
发表于 2025-3-25 12:27:05 | 显示全部楼层
发表于 2025-3-25 17:19:27 | 显示全部楼层
发表于 2025-3-25 20:10:34 | 显示全部楼层
Therapeutic challenges,nd slow down the decline in renal function. In type 1 diabetes, most proteinuria studies have used ACE inhibitors, whereas, for type 2 diabetes, ARBs have mostly been used. However, the American Diabetes Association (ADA) have concluded that the evidence was sufficient to state that both drug classe
发表于 2025-3-26 02:23:42 | 显示全部楼层
Fashions and fads,l nifedipine needed it about as much as a patient with high cholesterol would need a sublingual statin. Of note, there is good evidence that the sublingual application is of no added benefit because what gets into the blood stream is actually what is swallowed. Also, sublingual nifedipine lowers BP
发表于 2025-3-26 04:46:47 | 显示全部楼层
Gemeinsamer Vertreter der Gläubigeron of each drug to the overall outcome in a given patient. Progress has been made in identifying and understanding some drug interactions, allowing the rational combination of certain drugs in a given patient. Drug combinations may be rational for several reasons (Figure 10):
发表于 2025-3-26 11:37:06 | 显示全部楼层
发表于 2025-3-26 16:37:49 | 显示全部楼层
https://doi.org/10.37307/b.978-3-503-23631-2eta-blocker, diminishes glucose tolerance and increases the risk of new-onset diabetes. Conversely, as has been revealed in more recent trials, treatment with antihypertensive drugs, such as blockers of the RAS or calcium antagonists, appears to decrease this risk (Figure 25).
发表于 2025-3-26 17:20:50 | 显示全部楼层
Comorbid conditions,eta-blocker, diminishes glucose tolerance and increases the risk of new-onset diabetes. Conversely, as has been revealed in more recent trials, treatment with antihypertensive drugs, such as blockers of the RAS or calcium antagonists, appears to decrease this risk (Figure 25).
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-12 10:58
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表